Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
Top

05-07-2018 | FDA | News

approvalsWatch

Encorafenib–binimetinib approved for BRAF-mutated advanced melanoma

print
PRINT
insite
SEARCH

medwireNews: The US FDA has approved the use of encorafenib plus binimetinib for the treatment of unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.

Following results from the COLUMBUS trial, the combination of the BRAF inhibitor encorafenib 45 mg once daily and the MEK inhibitor binimetinib 45 mg twice daily may now be used by patients whose mutations have been confirmed by an FDA-approved test.

Side effects associated with treatment include fatigue, gastrointestinal adverse events and arthralgia, with hemorrhage and headache cited as the most frequent reasons for treatment discontinuation.

By Lynda Williams

medwireNews is an independent medical news service provided by Springer Healthcare. © 2018 Springer Healthcare part of the Springer Nature group

See also:

print
PRINT